Ken: ceftriaxone controlled study

[Guest guest]

OK, before you further elevate that particular study, keep in mind (A) the

participants

were selected to NOT have a positive lyme titre, and ( were not tested for

coinfections. If any did have coinfections of course they would not improve

healthwise from abx alone particularly of that class.

I suspect that the thing that divides the responders from the non-responders

with

regard to rocephin is largely (A) that they are indeed infected with Bb and (

they are

ONLY infected with Bb. If A AND B are true, they are probably responders. If A

OR B

are true or neither are, they are probably non-responders. I suspect this

hypothesis

would account for the data much better than anything thus far.

Further Ken, in the Krup study which also purportedly study the same treatment

regimen, there were indeed significant pre- and post-treatment differences in

subjective symptoms. Thus, once again the data remain equivocal.

Your interpretation and understanding of these studies is too simplistic as is

your

conclusion, " Patient reports of how they feel can not

> be relied on. "

> S. said

> " I now know several patients, have communicated with them, who have

> largely recovered from Lyme and attribute this primarily to

> ceftriaxone, and it does not even occur to me to doubt it.

>

> I know several patients, have communicated with them, who are

> deteriorating, who say to me 'I think it all went to hell on

> ceftriaxone,' and it does not even occur to me to doubt it. "

>

> Perhaps it should occur to you to doubt it. The site

> http://www.niaid.nih.gov/research/lyme.htm discusses the 2000

> ceftriaxone/doxy study which was stopped early due to lack of

> effectiveness.

>

> " After its review, the DSMB unanimously recommended that NIAID

> terminate the treatment component of these studies. Their

> preliminary analysis showed that after 90 days of continuous

> antibiotic therapy there were no significant differences in the

> percentage of patients who felt that their symptoms had improved,

> gotten worse, or stayed the same between the antibiotic treatment

> and placebo groups in either trial. "

>

> " It is noteworthy that in both the NEMC and SUNY clinical trials

> cited above, 40 percent of patients given placebo alone reported

> improvement in their symptoms (placebo effect). "

>

> This shows quite clearly the need for placebo controlled trials on

> any of these treatments, whether ceftriaxone, fluconazole, MP or any

> other. The need is even greater with CFS where the placebo effect

> could be in excess of 60%. Patient reports of how they feel can not

> be relied on.

>

> Ken